Solventum (NYSE:SOLV) Price Target Raised to $100.00

Solventum (NYSE:SOLV) had its price objective increased by stock analysts at Stifel Nicolaus from $90.00 to $100.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price target indicates a potential upside of 19.94% from the stock’s previous close.

A number of other equities research analysts have also recently weighed in on the company. Piper Sandler dropped their price objective on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Wells Fargo & Company dropped their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 6th. Weiss Ratings raised shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, July 17th. Mizuho set a $113.00 price objective on shares of Solventum in a research note on Thursday. Finally, BTIG Research lifted their price objective on shares of Solventum from $91.00 to $95.00 and gave the company a “buy” rating in a report on Thursday. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $89.82.

Solventum Trading Down 4.7%

Shares of NYSE:SOLV traded down $4.09 during mid-day trading on Thursday, reaching $83.38. 283,769 shares of the company were exchanged, compared to its average volume of 1,405,196. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The firm has a market cap of $14.44 billion, a price-to-earnings ratio of 10.30, a P/E/G ratio of 1.36 and a beta of 0.60. The firm’s 50-day simple moving average is $79.09 and its 200 day simple moving average is $74.36. Solventum has a 1 year low of $62.38 and a 1 year high of $90.00.

Solventum (NYSE:SOLV) last posted its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.64. The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Equities research analysts forecast that Solventum will post 6.58 EPS for the current year.

Institutional Trading of Solventum

Hedge funds and other institutional investors have recently made changes to their positions in the company. Assetmark Inc. lifted its stake in Solventum by 21.4% in the fourth quarter. Assetmark Inc. now owns 725 shares of the company’s stock valued at $57,000 after buying an additional 128 shares during the last quarter. BOKF NA increased its holdings in shares of Solventum by 6.9% in the 3rd quarter. BOKF NA now owns 2,193 shares of the company’s stock valued at $160,000 after acquiring an additional 141 shares during the period. Smartleaf Asset Management LLC boosted its stake in Solventum by 23.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 744 shares of the company’s stock worth $60,000 after purchasing an additional 142 shares during the period. NewEdge Advisors LLC grew its position in Solventum by 2.2% during the 1st quarter. NewEdge Advisors LLC now owns 6,707 shares of the company’s stock worth $438,000 after purchasing an additional 144 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators grew its position in Solventum by 39.5% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 516 shares of the company’s stock worth $41,000 after purchasing an additional 146 shares during the last quarter.

More Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Quarterly results exceeded expectations. Solventum reported second-quarter adjusted earnings of $2.55 per share, well above the $1.91 analyst consensus and up from $1.69 a year earlier. Revenue reached $2.21 billion, topping the $2.15 billion estimate, while reported sales rose 2.2% and organic sales increased 9.5%. Solventum Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year guidance was raised. Solventum increased its fiscal 2026 adjusted EPS outlook to $7.10-$7.20, above the roughly $6.55-$6.58 analyst expectation, while also raising its outlook for organic sales growth and free cash flow. Solventum outlines HIS separation and raises 2026 EPS guide
• Positive Sentiment: The HIS separation could unlock value. Management said it intends to separate its healthcare software business, allowing Solventum to focus on MedTech while giving HIS greater flexibility to pursue investment and growth as a standalone company. Solventum Announces Intent to Separate its Health Information Systems Business
• Negative Sentiment: Investors may be concerned about separation and execution risks. The HIS transaction, reportedly influenced by activist pressure, adds restructuring complexity and uncertainty over timing, costs, stranded expenses and the eventual value of the separated businesses. Solventum to hive off healthcare software business, raises profit forecast

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.